Kumarkrishna Raychaudhuri, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10 CRC. Rm. 1W-5940
- Bethesda, MD 20892
- 240-858-3700
- kumarkrishna.raychaudhuri@nih.gov
RESEARCH SUMMARY
At the Urologic Oncology Branch, Dr. Raychaudhuri’s research is focused on identifying novel therapeutic targets for various forms of renal cell malignancies. Despite our current understanding of specific molecular events, which result in oncogenic transformation and gives rise to distinct forms of renal cell cancers (RCC), the exact mechanism is far from clear. Dr. Raychaudhuri uses tools from cell biology, molecular biology, biochemistry, immunology, and mouse models to identify novel molecular mechanisms and targets.
Areas of Expertise
Biography
Kumarkrishna Raychaudhuri, Ph.D.
Dr. Raychaudhuri began his scientific career at the University of Calcutta, where he specialized in cytogenetics during his master’s studies. He earned his Ph.D. in Life Sciences from Homi Bhabha National Institute (HBNI) while working on tumorigenic and metastatic pathways underlying colon cancers at the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) facility of Tata Memorial Center (TMC), in India. During his doctoral work, he also collaborated with Dr. Jennifer Lippincott-Schwartz at NICHD to understand the role of 14-3-3 proteins in regulating focal adhesion dynamics. After completion of his Ph.D. in 2016, Dr. Raychaudhuri joined Dr. Rachel Caspi's lab at NEI for his postdoctoral research in cellular and functional immunology. In 2019, he joined Dr. Lawrence Samelson’s group in LCMB at NCI as a Visiting fellow and then subsequently transitioning to a Research fellow position. During this time, he identified a novel mechanism of function for CD28 co-stimulation using Jurkat T cells and primary T cells. Currently, Dr. Raychaudhuri is continuing his scientific research in Dr. Srinivasan’s group at UOB as a staff scientist.